Search

Your search keyword '"Montillo, Marco"' showing total 764 results
Start Over Author "Montillo, Marco"
764 results on '"Montillo, Marco"'

1. S201: FINAL 7‐YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX‐RITUXIMAB (VENR)‐TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

Author

Kater, Arnon, Harrup, Rosemary, Kipps, Thomas J, Eichhorst, Barbara, Owen, Carolyn J, Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Thadani‐Mulero, Maria, Lefebure, Marcus, Jiang, Yanwen, Millen, Rosemary, Boyer, Michelle, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Lymphatic Research, Cancer, Lymphoma, Rare Diseases, Hematology
Published
2023

2. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Author

Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, and Montillo, Marco

Published
2024
Full Text
View/download PDF

3. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Kater, Arnon P, Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H, van der Kevie-Kersemaekers, Anne-Marie F, Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J, Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E, Vizkelety, Tamas, and Forconi, Francesco

Published
2024
Full Text
View/download PDF

4. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Author

Kaufman, Matthew, Yan, Xiao-Jie, Li, Wentian, Ghia, Emanuela M, Langerak, Anton W, Rassenti, Laura Z, Belessi, Chrysoula, Kay, Neil E, Davi, Frederic, Byrd, John C, Pospisilova, Sarka, Brown, Jennifer R, Catherwood, Mark, Davis, Zadie, Oscier, David, Montillo, Marco, Trentin, Livio, Rosenquist, Richard, Ghia, Paolo, Barrientos, Jacqueline C, Kolitz, Jonathan E, Allen, Steven L, R., Kanti, Stamatopoulos, Kostas, Kipps, Thomas J, Neuberg, Donna, and Chiorazzi, Nicholas

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Lymphoma, Cancer, Hematology, Lymphatic Research, Rare Diseases, CLL, chronic lymphocytic leukemia, immunoglobulin variable domain, prognosis, somatic mutations, Oncology and Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the heart of the worse outcomes of CLL cases without/few IGHV mutations. A corollary of this conclusion is that M-CLL follow less aggressive clinical courses because somatic IGHV mutations have altered BCR structures and no longer bind stimulatory (auto)antigens and so cannot deliver trophic signals to leukemic B cells. However, the latter assumption has not been confirmed in a large patient cohort. We tried to address the latter by measuring the relative numbers of replacement (R) mutations that lead to non-conservative amino acid changes (Rnc) to the combined numbers of conservative (Rc) and silent (S) amino acid R mutations that likely do not or cannot change amino acids, "(S+Rc) to Rnc IGHV mutation ratio". When comparing time-to-first-treatment (TTFT) of patients with (S+Rc)/Rnc ≤ 1 and >1, TTFTs were similar, even after matching groups for equal numbers of samples and identical numbers of mutations per sample. Thus, BCR structural change might not be the main reason for better outcomes for M-CLL. Since the total number of IGHV mutations associated better with longer TTFT, better clinical courses appear due to the biologic state of a B cell having undergone many stimulatory events leading to IGHV mutations. Analyses of larger patient cohorts will be needed to definitively answer this question.

Published
2022

6. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

Author

Brown, Jennifer R, Zelenetz, Andrew, Furman, Richard, Lamanna, Nicole, Mato, Anthony, Montillo, Marco, O’Brien, Susan, Dubowy, Ronald, Gu, Lin, Munugalavadla, Veerendra, Robak, Tadeusz, and Hillmen, Peter

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Antineoplastic Agents, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Purines, Quinazolinones, Risk Factors, Transaminases, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Published
2020

7. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, Arnon P, Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R, Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Lymphoma, Genetics, Rare Diseases, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Bridged Bicyclo Compounds, Heterocyclic, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Karyopherins, Leukemia, Lymphocytic, Chronic, B-Cell, Mutation, Progression-Free Survival, Proto-Oncogene Proteins B-raf, Receptor, Notch1, Receptors, Cytoplasmic and Nuclear, Rituximab, Sulfonamides, Treatment Outcome, Tumor Suppressor Protein p53, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics.Patients and methodsPatients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed.ResultsOf 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT.ConclusionEfficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

8. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Author

Munir, Talha, Brown, Jennifer R, O'Brien, Susan, Barrientos, Jacqueline C, Barr, Paul M, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine S, Mulligan, Stephen P, Jaeger, Ulrich, Kipps, Thomas J, Moreno, Carol, Montillo, Marco, Burger, Jan A, Byrd, John C, Hillmen, Peter, Dai, Sandra, Szoke, Anita, Dean, James P, and Woyach, Jennifer A

Subjects
Lymphoma, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Cardiovascular Diseases, Female, Follow-Up Studies, Hematologic Diseases, Humans, Infections, Kaplan-Meier Estimate, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Progression-Free Survival, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines, Remission Induction, Risk, Salvage Therapy, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single-agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high-risk features. Here we report the final analysis from RESONATE with median follow-up on study of 65.3 months (range, 0.3-71.6) in the ibrutinib arm. Median progression-free survival (PFS) remained significantly longer for patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113-0.196; P˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high-risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080-0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418-0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all-grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long-term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high-risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707).

Published
2019

9. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, and Kater, Arnon P.

Published
2022
Full Text
View/download PDF

11. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Author

Tedeschi, Alessandra, Frustaci, Anna Maria, Mauro, Francesca Romana, Chiarenza, Annalisa, Coscia, Marta, Ciolli, Stefania, Reda, Gianluigi, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Baratè, Claudia, Sportoletti, Paolo, Greco, Antonino, Borella, Chiara, Rossi, Valentina, Deodato, Marina, Biagi, Annalisa, Zamprogna, Giulia, Pelle, Angelo Curto, Lapietra, Gianfranco, Vitale, Candida, Morelli, Francesca, Cassin, Ramona, Fresa, Alberto, Cavalloni, Chiara, Postorino, Massimiliano, Ielo, Claudia, Cairoli, Roberto, Di Raimondo, Francesco, Montillo, Marco, and Del Poeta, Giovanni

Published
2021
Full Text
View/download PDF

12. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Author

Agathangelidis, Andreas, Chatzidimitriou, Anastasia, Gemenetzi, Katerina, Giudicelli, Veronique, Karypidou, Maria, Plevova, Karla, Davis, Zadie, Yan, Xiao-Jie, Jeromin, Sabine, Schneider, Christof, Pedersen, Lone Bredo, Tschumper, Renee C., Sutton, Lesley-Ann, Baliakas, Panagiotis, Scarfò, Lydia, van Gastel, Ellen J., Armand, Marine, Tausch, Eugen, Biderman, Bella, Baer, Constance, Bagnara, Davide, Navarro, Alba, Langlois de Septenville, Anne, Guido, Valentina, Mitterbauer-Hohendanner, Gerlinde, Dimovski, Aleksandar, Brieghel, Christian, Lawless, Sarah, Meggendorfer, Manja, Brazdilova, Kamila, Ritgen, Matthias, Facco, Monica, Tresoldi, Cristina, Visentin, Andrea, Patriarca, Andrea, Catherwood, Mark, Bonello, Lisa, Sudarikov, Andrey, Vanura, Katrina, Roumelioti, Maria, Skuhrova Francova, Hana, Moysiadis, Theodoros, Veronese, Silvio, Giannopoulos, Krzysztof, Mansouri, Larry, Karan-Djurasevic, Teodora, Sandaltzopoulos, Raphael, Bödör, Csaba, Fais, Franco, Kater, Arnon, Panovska, Irina, Rossi, Davide, Alshemmari, Salem, Panagiotidis, Panagiotis, Costeas, Paul, Espinet, Blanca, Antic, Darko, Foroni, Letizia, Montillo, Marco, Trentin, Livio, Stavroyianni, Niki, Gaidano, Gianluca, Francia di Celle, Paola, Niemann, Carsten, Campo, Elias, Anagnostopoulos, Achilles, Pott, Christiane, Fischer, Kirsten, Hallek, Michael, Oscier, David, Stilgenbauer, Stephan, Haferlach, Claudia, Jelinek, Diane, Chiorazzi, Nicholas, Pospisilova, Sarka, Lefranc, Marie-Paule, Kossida, Sofia, Langerak, Anton W., Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2021
Full Text
View/download PDF

13. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, Forconi, Francesco, Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, and Forconi, Francesco

Published
2024

14. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Author

Tedeschi, A, Frustaci, A, Condoluci, A, Coscia, M, Chiarle, R, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Catania, G, Deodato, M, Jones, R, Tabanelli, V, Griggio, V, Stüssi, G, Calleri, A, Pini, K, Cairoli, R, Zenz, T, Signori, A, Zucca, E, Rossi, D, Montillo, M, Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, Montillo, Marco, Tedeschi, A, Frustaci, A, Condoluci, A, Coscia, M, Chiarle, R, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Catania, G, Deodato, M, Jones, R, Tabanelli, V, Griggio, V, Stüssi, G, Calleri, A, Pini, K, Cairoli, R, Zenz, T, Signori, A, Zucca, E, Rossi, D, Montillo, M, Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, and Montillo, Marco

Published
2024

15. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Author

Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, and Stilgenbauer, Stephan

Published
2018
Full Text
View/download PDF

16. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Author

Byrd, John C, Brown, Jennifer R, O'Brien, Susan, Barrientos, Jacqueline C, Kay, Neil E, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine S, Mulligan, Stephen P, Jaeger, Ulrich, Devereux, Steve, Barr, Paul M, Furman, Richard R, Kipps, Thomas J, Cymbalista, Florence, Pocock, Christopher, Thornton, Patrick, Caligaris-Cappio, Federico, Robak, Tadeusz, Delgado, Julio, Schuster, Stephen J, Montillo, Marco, Schuh, Anna, de Vos, Sven, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Jones, Jeffrey J, Chu, Alvina D, Fardis, Maria, McGreivy, Jesse, Clow, Fong, James, Danelle F, and Hillmen, Peter

Subjects
Lymphoma, Rare Diseases, Orphan Drug, Clinical Research, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Agammaglobulinaemia Tyrosine Kinase, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cough, Diarrhea, Disease-Free Survival, Fatigue, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Rate, RESONATE Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundIn patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.MethodsIn this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.ResultsAt a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P

Published
2014

17. S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Author

Frustaci, Anna Maria, primary, Montillo, Marco, additional, Rossi, Davide, additional, Zinzani, Pier Luigi, additional, Motta, Marina, additional, Gaidano, Gianluca, additional, Quaresmini, Giulia, additional, Scarfò, Lydia, additional, Pietrasanta, Daniela, additional, Coscia, Marta, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Cairoli, Roberto, additional, Stüssi, Georg, additional, Zucca, Emanuele, additional, Pileri, Stefano, additional, Zenz, Thorsten, additional, and Tedeschi, Alessandra, additional

Published
2023
Full Text
View/download PDF

18. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Author

Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., and Byrd, John C.

Published
2017
Full Text
View/download PDF

19. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Author

Zelenetz, Andrew D, Barrientos, Jacqueline C, Brown, Jennifer R, Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S, Robak, Tadeusz, Sharman, Jeff P, Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H, Dreiling, Lyndah K, Kim, Yeonhee, Stilgenbauer, Stephan, and Hillmen, Peter

Published
2017
Full Text
View/download PDF

20. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

21. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, primary, Kavakiotis, Ioannis, primary, Agathangelidis, Andreas, primary, Sutton, Lesley-Ann, primary, Minga, Eva, primary, Ntoufa, Stavroula, primary, Tausch, Eugen, primary, Yan, Xiao-Jie, primary, Shanafelt, Tait, primary, Plevova, Karla, primary, Boudjogra, Myriam, primary, Rossi, Davide, primary, Davis, Zadie, primary, Navarro, Alba, primary, Sandberg, Yorick, primary, Vojdeman, Fie Juhl, primary, Scarfo, Lydia, primary, Stavroyianni, Niki, primary, Sudarikov, Andrey, primary, Veronese, Silvio, primary, Tzenou, Tatiana, primary, Karan-Djurasevic, Teodora, primary, Catherwood, Mark, primary, Kienle, Dirk, primary, Chatzouli, Maria, primary, Facco, Monica, primary, Bahlo, Jasmin, primary, Pott, Christiane, primary, Pedersen, Lone Bredo, primary, Mansouri, Larry, primary, Smedby, Karin E., primary, Chu, Charles C., primary, Giudicelli, Véronique, primary, Lefranc, Marie-Paule, primary, Panagiotidis, Panagiotis, primary, Juliusson, Gunnar, primary, Anagnostopoulos, Achilles, primary, Vlahavas, Ioannis, primary, Antic, Darko, primary, Trentin, Livio, primary, Montillo, Marco, primary, Niemann, Carsten, primary, Döhner, Hartmut, primary, Langerak, Anton W., primary, Pospisilova, Sarka, primary, Hallek, Michael, primary, Campo, Elias, primary, Chiorazzi, Nicholas, primary, Maglaveras, Nikos, primary, Oscier, David, primary, Gaidano, Gianluca, primary, Jelinek, Diane F., primary, Stilgenbauer, Stephan, primary, Chouvarda, Ioanna, primary, Darzentas, Nikos, primary, Belessi, Chrysoula, primary, Davi, Frederic, primary, Hadzidimitriou, Anastasia, primary, Rosenquist, Richard, primary, Ghia, Paolo, primary, and Stamatopoulos, Kostas, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2A from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

24. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, primary, Kavakiotis, Ioannis, primary, Agathangelidis, Andreas, primary, Sutton, Lesley-Ann, primary, Minga, Eva, primary, Ntoufa, Stavroula, primary, Tausch, Eugen, primary, Yan, Xiao-Jie, primary, Shanafelt, Tait, primary, Plevova, Karla, primary, Boudjogra, Myriam, primary, Rossi, Davide, primary, Davis, Zadie, primary, Navarro, Alba, primary, Sandberg, Yorick, primary, Vojdeman, Fie Juhl, primary, Scarfo, Lydia, primary, Stavroyianni, Niki, primary, Sudarikov, Andrey, primary, Veronese, Silvio, primary, Tzenou, Tatiana, primary, Karan-Djurasevic, Teodora, primary, Catherwood, Mark, primary, Kienle, Dirk, primary, Chatzouli, Maria, primary, Facco, Monica, primary, Bahlo, Jasmin, primary, Pott, Christiane, primary, Pedersen, Lone Bredo, primary, Mansouri, Larry, primary, Smedby, Karin E., primary, Chu, Charles C., primary, Giudicelli, Véronique, primary, Lefranc, Marie-Paule, primary, Panagiotidis, Panagiotis, primary, Juliusson, Gunnar, primary, Anagnostopoulos, Achilles, primary, Vlahavas, Ioannis, primary, Antic, Darko, primary, Trentin, Livio, primary, Montillo, Marco, primary, Niemann, Carsten, primary, Döhner, Hartmut, primary, Langerak, Anton W., primary, Pospisilova, Sarka, primary, Hallek, Michael, primary, Campo, Elias, primary, Chiorazzi, Nicholas, primary, Maglaveras, Nikos, primary, Oscier, David, primary, Gaidano, Gianluca, primary, Jelinek, Diane F., primary, Stilgenbauer, Stephan, primary, Chouvarda, Ioanna, primary, Darzentas, Nikos, primary, Belessi, Chrysoula, primary, Davi, Frederic, primary, Hadzidimitriou, Anastasia, primary, Rosenquist, Richard, primary, Ghia, Paolo, primary, and Stamatopoulos, Kostas, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 3 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

28. Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Author

Trojani, A, Beghini, A, Bossi, L, Stefanucci, M, Palumbo, C, Greco, A, Frustaci, A, Di Camillo, B, Montillo, M, Cairoli, R, Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, Montillo, Marco, Cairoli, Roberto, Trojani, A, Beghini, A, Bossi, L, Stefanucci, M, Palumbo, C, Greco, A, Frustaci, A, Di Camillo, B, Montillo, M, Cairoli, R, Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, Montillo, Marco, and Cairoli, Roberto

Published
2023

29. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome

Author

Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, Tedeschi, Alessandra, Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, and Tedeschi, Alessandra

Published
2023

30. Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Author

Frustaci, A, Deodato, M, Zamprogna, G, Cairoli, R, Montillo, M, Tedeschi, A, Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Montillo, Marco, Tedeschi, Alessandra, Frustaci, A, Deodato, M, Zamprogna, G, Cairoli, R, Montillo, M, Tedeschi, A, Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Montillo, Marco, and Tedeschi, Alessandra

Abstract

Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially for high-risk patients, and include BTK inhibitor combinations with BCl2 inhibitors with or without anti-CD20 monoclonal antibodies. Finally, new mechanisms for BTK inhibition are under investigations in patients progressing with both covalent and non-covalent BTK and BCl2 inhibitors. Here we summarize and discuss results from main experiences on irreversible and reversable BTK inhibitors in CLL.

Published
2023

33. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Author

Hillmen, Peter, Robak, Tadeusz, Janssens, Ann, Babu, K Govind, Kloczko, Janusz, Grosicki, Sebastian, Doubek, Michael, Panagiotidis, Panagiotis, Kimby, Eva, Schuh, Anna, Pettitt, Andrew R, Boyd, Thomas, Montillo, Marco, Gupta, Ira V, Wright, Oliver, Dixon, Iestyn, Carey, Jodi L, Chang, Chai-Ni, Lisby, Steen, McKeown, Astrid, and Offner, Fritz

Published
2015
Full Text
View/download PDF

34. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study

Author

Baliakas, Panagiotis, Hadzidimitriou, Anastasia, Sutton, Lesley-Ann, Minga, Eva, Agathangelidis, Andreas, Nichelatti, Michele, Tsanousa, Athina, Scarfò, Lydia, Davis, Zadie, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Sandberg, Yorick, Vojdeman, Fie Juhl, Boudjogra, Myriam, Tzenou, Tatiana, Chatzouli, Maria, Chu, Charles C, Veronese, Silvio, Gardiner, Anne, Mansouri, Larry, Smedby, Karin E, Pedersen, Lone Bredo, van Lom, Kirsten, Giudicelli, Véronique, Francova, Hana Skuhrova, Nguyen-Khac, Florence, Panagiotidis, Panagiotis, Juliusson, Gunnar, Angelis, Lefteris, Anagnostopoulos, Achilles, Lefranc, Marie-Paule, Facco, Monica, Trentin, Livio, Catherwood, Mark, Montillo, Marco, Geisler, Christian H, Langerak, Anton W, Pospisilova, Sarka, Chiorazzi, Nicholas, Oscier, David, Jelinek, Diane F, Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2014
Full Text
View/download PDF

36. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, DʼRozario, James, Assouline, Sarit, Owen, Carolyn, Gerecitano, John, Robak, Tadeusz, De la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Humerickhouse, Rod, Punnoose, Elizabeth A., Li, Yan, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, and Kater, Arnon P.

Published
2018
Full Text
View/download PDF

37. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Author

Kaufman, Matthew, primary, Yan, Xiao-Jie, additional, Li, Wentian, additional, Ghia, Emanuela M., additional, Langerak, Anton W., additional, Rassenti, Laura Z., additional, Belessi, Chrysoula, additional, Kay, Neil E., additional, Davi, Frederic, additional, Byrd, John C., additional, Pospisilova, Sarka, additional, Brown, Jennifer R., additional, Catherwood, Mark, additional, Davis, Zadie, additional, Oscier, David, additional, Montillo, Marco, additional, Trentin, Livio, additional, Rosenquist, Richard, additional, Ghia, Paolo, additional, Barrientos, Jacqueline C., additional, Kolitz, Jonathan E., additional, Allen, Steven L., additional, Rai, Kanti R., additional, Stamatopoulos, Kostas, additional, Kipps, Thomas J., additional, Neuberg, Donna, additional, and Chiorazzi, Nicholas, additional

Published
2022
Full Text
View/download PDF

40. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Author

Dufour, Annika, Palermo, Giuseppe, Zellmeier, Evelyn, Mellert, Gudrun, Duchateau-Nguyen, Guillemette, Schneider, Stephanie, Benthaus, Tobias, Kakadia, Purvi M., Spiekermann, Karsten, Hiddemann, Wolfgang, Braess, Jan, Truong, Sim, Patten, Nancy, Wu, Lin, Lohmann, Sabine, Dornan, David, GuhaThakurta, Debraj, Yeh, Ru-Fang, Salogub, Galina, Solal-Celigny, Philippe, Dmoszynska, Anna, Robak, Tadeusz, Montillo, Marco, Catalano, John, Geisler, Christian H., Weisser, Martin, and Bohlander, Stefan K.

Published
2013
Full Text
View/download PDF

41. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, Laurenti, Luca (ORCID:0000-0002-8327-1396), Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

NA

Published
2022

43. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, primary, Frustaci, Anna Maria, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Murru, Roberta, additional, Visentin, Andrea, additional, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Quaresmini, Giulia, additional, Vanazzi, Anna, additional, Vitale, Candida, additional, Orsucci, Lorella, additional, Massaia, Massimo, additional, Sanna, Alessandro, additional, Motta, Marina, additional, Ibatici, Adalberto, additional, Ferrarini, Isacco, additional, Borella, Chiara, additional, Varettoni, Marzia, additional, Tani, Monica, additional, Marinoni, Sara, additional, Ferrario, Andrea, additional, Zamprogna, Giulia, additional, Montillo, Marco, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

44. sj-docx-1-tah-10.1177_20406207221127550 – Supplemental material for Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Author

Frustaci, Anna Maria, Del Poeta, Giovanni, Visentin, Andrea, Sportoletti, Paolo, Fresa, Alberto, Vitale, Candida, Murru, Roberta, Chiarenza, Annalisa, Sanna, Alessandro, Mauro, Francesca Romana, Reda, Gianluigi, Gentile, Massimo, Varettoni, Marzia, Baratè, Claudia, Borella, Chiara, Greco, Antonino, Deodato, Marina, Zamprogna, Giulia, Laureana, Roberta, Cipiciani, Alessandra, Galitzia, Andrea, Curto Pelle, Angelo, Morelli, Francesca, Malvisi, Lucio, Coscia, Marta, Laurenti, Luca, Trentin, Livio, Montillo, Marco, Cairoli, Roberto, and Tedeschi, Alessandra

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207221127550 for Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia by Anna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, Paolo Sportoletti, Alberto Fresa, Candida Vitale, Roberta Murru, Annalisa Chiarenza, Alessandro Sanna, Francesca Romana Mauro, Gianluigi Reda, Massimo Gentile, Marzia Varettoni, Claudia Baratè, Chiara Borella, Antonino Greco, Marina Deodato, Giulia Zamprogna, Roberta Laureana, Alessandra Cipiciani, Andrea Galitzia, Angelo Curto Pelle, Francesca Morelli, Lucio Malvisi, Marta Coscia, Luca Laurenti, Livio Trentin, Marco Montillo, Roberto Cairoli and Alessandra Tedeschi in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

45. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Author

Frustaci, Anna Maria, primary, Del Poeta, Giovanni, additional, Visentin, Andrea, additional, Sportoletti, Paolo, additional, Fresa, Alberto, additional, Vitale, Candida, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sanna, Alessandro, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Gentile, Massimo, additional, Varettoni, Marzia, additional, Baratè, Claudia, additional, Borella, Chiara, additional, Greco, Antonino, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Laureana, Roberta, additional, Cipiciani, Alessandra, additional, Galitzia, Andrea, additional, Curto Pelle, Angelo, additional, Morelli, Francesca, additional, Malvisi, Lucio, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Trentin, Livio, additional, Montillo, Marco, additional, Cairoli, Roberto, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

47. Effect of FCGR2A and FCGR3A variants on CLL outcome

Author

Dornan, David, Spleiss, Olivia, Yeh, Ru-Fang, Duchateau-Nguyen, Guillemette, Dufour, Annika, Zhi, Jianguo, Robak, Tadeusz, Moiseev, Sergey I., Dmoszynska, Anna, Solal-Celigny, Philippe, Warzocha, Krzysztof, Loscertales, Javier, Catalano, John, Afanasiev, Boris V., Larratt, Loree, Rossiev, Viktor A., Bence-Bruckler, Isabelle, Geisler, Christian H., Montillo, Marco, Wenger, Michael K., and Weisser, Martin

Published
2010
Full Text
View/download PDF

49. Genetic Landscape and Clonal Evolution Patterns of CEBPA-Mutated Acute Myeloid Leukaemia Based on Next-Generation Sequencing: A Retrospective Analysis

Author

Leuzzi, Livia, primary, Mancini, Valentina, additional, Veronese, Silvio Marco, additional, Pezzetti, Laura, additional, Motta, Valentina, additional, Nichelatti, Michele, additional, Greco, Rosa, additional, Bertani, Giambattista, additional, Montillo, Marco, additional, Beghini, Alessandro, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

50. Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance (IgM MGUS) Compared to Healthy Subjects

Author

Trojani, Alessandra, primary, Di Camillo, Barbara, additional, Bossi, Luca Emanuele, additional, Greco, Antonino, additional, Leuzzi, Livia, additional, Tedeschi, Alessandra, additional, Frustaci, Anna Maria, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Melluso, Agostina, additional, Panzeri, Alessia, additional, Montillo, Marco, additional, Beghini, Alessandro, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results